Annaliesa S Anderson Selected Research

factor A

3/2016	Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection.
10/2015	Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection.
5/2009	Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Annaliesa S Anderson Research Topics

Disease

25	Infections 01/2022 - 09/2003
12	Meningococcal Infections 01/2020 - 08/2010
7	COVID-19 01/2022 - 11/2020
3	Cross Infection (Nosocomial Infection) 01/2020 - 04/2006
3	Bacteremia 09/2013 - 05/2009
2	Pain (Aches) 01/2021 - 01/2020
2	Sepsis (Septicemia) 01/2017 - 06/2013
2	Wound Infection (Wound Infections) 09/2013 - 05/2009
2	Wounds and Injuries (Trauma) 06/2013 - 09/2003
2	Staphylococcal Infections 01/2013 - 09/2003
1	Otitis Media 12/2022
1	Pharyngitis (Sore Throat) 12/2022
1	Community-Acquired Infections 01/2020
1	Diarrhea 01/2020
1	Streptococcal Infections (Streptococcal Infection) 01/2019
1	Meningococcal Meningitis 11/2016
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2014
1	Soft Tissue Infections 06/2013
1	Chronic Kidney Failure (Chronic Renal Failure) 06/2013
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2013
1	Tissue Adhesions 10/2012
1	Abscess 09/2003
1	Foreign Bodies (Foreign Body) 09/2003
1	Persistent Infection 09/2003

Drug/Important Bio-Agent (IBA)

30	VaccinesIBA 01/2022 - 04/2006
8	AntigensIBA 01/2020 - 05/2009
6	Antiviral Agents (Antivirals)IBA 01/2022 - 02/2021
5	Anti-Bacterial Agents (Antibiotics)IBA 12/2022 - 09/2003
5	Polysaccharides (Glycans)IBA 01/2022 - 05/2009
4	AntibodiesIBA 01/2020 - 05/2009
4	Carrier Proteins (Binding Protein)IBA 01/2017 - 08/2010
3	Complement Factor H (Factor H)IBA 01/2017 - 08/2010
3	Proteins (Proteins, Gene)FDA Link 03/2016 - 05/2009
3	factor AIBA 03/2016 - 05/2009
2	lufotrelvirIBA 02/2021 - 02/2021
2	remdesivirIBA 02/2021 - 02/2021
2	Complement System Proteins (Complement)IBA 01/2020 - 01/2017
2	Conjugate VaccinesIBA 01/2019 - 10/2018
2	Capsules (Microcapsules)IBA 01/2016 - 01/2014
2	Virulence Factors (Pathogenicity Factors)IBA 01/2014 - 10/2012
1	O Antigens (O Antigen)IBA 01/2022
1	nirmatrelvirIBA 01/2022
1	GlycoconjugatesIBA 01/2022
1	Protease Inhibitors (Protease Inhibitor)IBA 10/2021
1	Peptide Hydrolases (Proteases)FDA Link 02/2021
1	AntipyreticsIBA 01/2021
1	SolutionsIBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	LipidsIBA 11/2016
1	Lipoproteins (Lipoprotein)IBA 11/2016
1	ElementsIBA 09/2016
1	Immune Sera (Antisera)IBA 08/2015
1	Formaldehyde (Formol)FDA Link 07/2013
1	Fibrinogen (Factor I)FDA Link 10/2012
1	CoagulaseIBA 10/2012
1	Neisseria meningitidis factor H-binding proteinIBA 11/2010
1	Immunoglobulin G (IgG)IBA 05/2009
1	IronIBA 05/2009
1	Methicillin (Metin)FDA Link 04/2006
1	aluminum hydroxyphosphate sulfateIBA 04/2006
1	Linezolid (Zyvox)FDA Link 09/2003

Therapy/Procedure

3	Therapeutics 12/2021 - 09/2003
2	Prostheses and Implants (Prosthesis) 06/2013 - 09/2003
1	Intramuscular Injections 01/2021
1	Spinal Fusion (Spondylosyndesis) 01/2017
1	Renal Dialysis (Hemodialysis) 06/2013
1	Catheters 09/2003